Spots Global Cancer Trial Database for head and neck squamous cell carcinoma
Every month we try and update this database with for head and neck squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma | NCT04440917 | Head and Neck S... | Camrelizumab Apatinib Mesyla... | 18 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC) | NCT02345330 | Head and Neck S... | Tavokinogene Te... OncoSec Medical... | 18 Years - | OncoSec Medical Incorporated | |
| Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC | NCT04399785 | Head and Neck S... | Camrelizumab an... | 18 Years - | West China Hospital | |
| TRACE: Tirapazamine-Radiation And Cisplatin Evaluation | NCT00174837 | Head and Neck S... | Tirapazamine Cisplatin | 18 Years - | Sanofi | |
| Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | NCT04361409 | Head and Neck S... | Rituximab Cisplatin Gemcitabine | 20 Years - 65 Years | China Medical University Hospital | |
| Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) | NCT04675294 | Head and Neck C... Head and Neck S... | evorpacept pembrolizumab | 18 Years - | ALX Oncology Inc. | |
| Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China | NCT04740996 | Head and Neck S... | Pembrolizumab | 18 Years - | ChineseAMS | |
| 3D Specimen Maps for RT Planning | NCT05743569 | Head and Neck C... Head and Neck S... Radiation Thera... | 28 Years - | Vanderbilt University Medical Center | ||
| PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC | NCT02544880 | Head and Neck S... Head and Neck C... | Tadalafil Anti-MUC1 Vacci... Anti-Influenza ... Tadalafil Place... Anti-MUC1 Vacci... Standard of Car... Anti-Influenza ... | 18 Years - | University of Miami | |
| UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | NCT03474497 | Non Small Cell ... Metastatic Mela... Metastatic Rena... Head and Neck S... | IL-2 Pembrolizumab Radiotherapy | 18 Years - | University of California, Davis | |
| Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC | NCT05516589 | Head and Neck S... | Nab-paclitaxel Cisplatin Tislelizumab Afatinib | 18 Years - | West China Hospital | |
| A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | NCT05229601 | Soft Tissue Sar... Renal Cell Carc... Uterine Carcino... Hepatocellular ... Head and Neck S... Melanoma | HFB301001 | 18 Years - | HiFiBiO Therapeutics | |
| Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma | NCT04093115 | Head and Neck S... | CX1106 | 18 Years - | Beijing Konruns Pharmaceutical Co., Ltd. | |
| The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR | NCT05854823 | Head and Neck S... | dose-reduced ra... | 18 Years - 70 Years | Fifth Affiliated Hospital, Sun Yat-Sen University | |
| Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study. | NCT06162377 | Head and Neck S... | Methylnaltrexon... | 18 Years - | M.D. Anderson Cancer Center | |
| Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | NCT03916627 | Non-small Cell ... Hepatocellular ... Head and Neck S... | cemiplimab Platinum Double... fianlimab | 18 Years - | Regeneron Pharmaceuticals | |
| A Study of NX-1607 in Adults With Advanced Malignancies | NCT05107674 | Ovarian Cancer,... Gastric Cancer GastroEsophagea... Head and Neck S... Metastatic or U... Non-small Cell ... Metastatic Cast... Malignant Pleur... Triple Negative... Metastatic Urot... Cervical Cancer Diffuse Large B... Richter Transfo... Microsatellite ... | NX-1607 Paclitaxel | 18 Years - | Nurix Therapeutics, Inc. | |
| SPIO-enhanced MRI in Oral Cancer for Sentinel Lymph Node Identification | NCT04803331 | Head and Neck S... | SPIO-enhanced M... | 18 Years - | Radboud University Medical Center | |
| Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC | NCT03450967 | Head and Neck S... | Durvalumab Plus... | 20 Years - | Samsung Medical Center | |
| Transoral Robotic Surgery and Tailored Radiotherapy in Unknown Primary and Small Squamous Cell Head and Neck Cancer | NCT03281499 | Head and Neck S... | da Vinci Surgic... | 18 Years - | University Health Network, Toronto | |
| Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1. | NCT03666273 | Advanced Solid ... Head and Neck S... | Bapotulimab (BA... Bapotulimab (BA... | 18 Years - | Bayer | |
| Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | NCT03336606 | Head and Neck C... Head and Neck S... Melanoma Cell Cancer, Sq... Carcinoma, Squa... | MEDI0562 | 18 Years - | Providence Health & Services | |
| Phase Ib of L-NMMA and Pembrolizumab | NCT03236935 | Non-Small Cell ... Malignant Melan... Head and Neck S... Classical Hodgk... Urothelial Carc... DNA Repair-Defi... | L-NMMA Pembrolizumab | 18 Years - | The Methodist Hospital Research Institute | |
| Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | NCT03370276 | Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Head and Neck S... Squamous Cell C... Head and Neck C... | Nivolumab Cetuximab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC | NCT04826679 | Head and Neck S... | Camrelizumab, n... | 18 Years - 65 Years | Sun Yat-sen University | |
| Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors | NCT05117138 | Melanoma Non-small Cell ... Head and Neck S... | AMT-116 CAR-T c... AMT-253 CAR-T c... | 18 Years - 70 Years | Beijing Immunochina Medical Science & Technology Co., Ltd. | |
| Anti-tumor Specific Immune Response in Head and Neck Cancers | NCT02881918 | Head and Neck S... | Blood sample | 18 Years - | Central Hospital, Nancy, France | |
| Pazopanib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT01377298 | Head and Neck S... | Pazopanib | 18 Years - 70 Years | National Taiwan University Hospital | |
| Reactivating NK Cells in Treating Refractory Head and Neck Cancer | NCT02507154 | Nasopharyngeal ... Head and Neck S... | Cetuximab + NK ... | 21 Years - | National University Hospital, Singapore | |
| A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | NCT05877599 | Non-small Cell ... Head and Neck S... Colorectal Carc... Pancreatic Aden... Breast Cancer Other Solid Tum... | Autologous, eng... | 18 Years - | Neogene Therapeutics, Inc. | |
| Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer | NCT05936502 | Head and Neck S... Extranodal Exte... Human Papilloma... | Extranodal exte... | 18 Years - | Head and Neck Cancer International Group | |
| Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | NCT03283605 | Head and Neck S... Metastatic Squa... | SBRT Durvalumab Tremelimumab | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure | NCT04278092 | Head and Neck S... | Paclitaxel Cetuximab | 18 Years - | Medical University of Vienna | |
| Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | NCT05585034 | Head and Neck S... Melanoma Exclud... Non-small Cell ... Urothelial Carc... Renal Cell Carc... Castration-resi... Ovarian Cancer,... TNBC - Triple-N... Colorectal Canc... | XmAb®808 Keytruda® (pemb... | 18 Years - | Xencor, Inc. | |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | NCT04485013 | Cancer | TTX-080 TTX-080 pembrolizumab cetuximab | 18 Years - | Tizona Therapeutics, Inc | |
| Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma | NCT06323369 | Head and Neck S... | Tislelizumab（ne... Cisplatin （neoa... Nab-paclitaxel ... Surgical resect... Cisplatin（adjuv... Tislelizumab（ad... Radiation Carboplatin（neo... Carboplatin（adj... | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer | NCT03578406 | Cervical Cancer Head and Neck S... | HPV E6-specific... | 18 Years - 70 Years | Xinqiao Hospital of Chongqing | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| Study of SCB01A in Patient With Head and Neck Cancer | NCT02488629 | Head and Neck S... | SCB01A | 20 Years - | SynCore Biotechnology Co., Ltd. | |
| Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC | NCT04681469 | Head and Neck S... | Niraparib | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC | NCT02639858 | Head and Neck S... | Docetaxel-PM | 20 Years - 79 Years | Samyang Biopharmaceuticals Corporation | |
| Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN | NCT03878979 | Head and Neck S... Head and Neck C... Head and Neck C... | Nivolumab 480mg... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Vaccination With Flt3L, Radiation, and Poly-ICLC | NCT03789097 | Non-Hodgkin's L... Metastatic Brea... Head and Neck S... | Pembrolizumab Flt3L Radiation Poly ICLC | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| A Study of LY3435151 in Participants With Solid Tumors | NCT04099277 | Solid Tumor Triple-negative... Gastric Adenoca... Head and Neck S... Cervical Carcin... High Grade Sero... Hepatocellular ... Undifferentiate... Leiomyosarcoma | LY3435151 Pembrolizumab | 18 Years - | Eli Lilly and Company | |
| ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | NCT06357858 | Recurrent Squam... Metastatic Squa... Head and Neck S... | INQOVI (decitab... Nivolumab | 19 Years - | Case Comprehensive Cancer Center | |
| Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate | NCT03134846 | Head and Neck S... Margin Assessme... | Cetuximab-IRDye... | 18 Years - | University Medical Center Groningen | |
| Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer | NCT03405142 | Head and Neck S... Squamous Cell C... Head and Neck C... | Panitumumab-IRD... Lymphoseek | 19 Years - | Stanford University | |
| 2B or Not 2B? Shoulder Function After Level 2B Neck Dissection: A Randomized Controlled Study | NCT00765791 | Head and Neck S... | Selective Neck ... Selective Neck ... | 18 Years - 100 Years | University of Alberta | |
| Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 | NCT03838601 | Head and Neck S... | MET-4 | 18 Years - | University Health Network, Toronto | |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | NCT06084845 | Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Oral Cavity Squ... Oropharyngeal S... Stage III Cutan... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Cutane... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha... | Biospecimen Col... Carboplatin Chest Radiograp... Cisplatin Computed Tomogr... Image Guided Ra... Intensity-Modul... Magnetic Resona... Positron Emissi... Xevinapant | 18 Years - | Eastern Cooperative Oncology Group | |
| Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma | NCT05189184 | Head and Neck S... | Camrelizumab+Ap... | 18 Years - 75 Years | The First Affiliated Hospital of Zhengzhou University | |
| Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT) | NCT04523883 | Head and Neck S... | postoperative r... JS001 | 18 Years - | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) | NCT04807140 | Head and Neck S... | Toripalimab, na... Toripalimab Surgical resect... | 18 Years - 80 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | NCT05172258 | Head and Neck S... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha... | Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Pembrolizumab | 18 Years - | National Cancer Institute (NCI) | |
| A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer | NCT03212469 | Head and Neck S... Lung Cancer Oesophageal Can... | Durvalumab Tremelimumab SBRT | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients | NCT02143622 | Head and Neck S... | LJM716 cetuximab | 18 Years - | Novartis | |
| Prognostic Impact of Tumor Growth Velocity in Head and Neck Squamous Cell Carcinoma Treated by Radio(Chemo)Therapy | NCT02990936 | Head and Neck S... Tumor Growth | Tumor delineati... | 18 Years - | Centre Hospitalier Universitaire UCLouvain Namur | |
| Study of Pembrolizumab Combined With Chemotherapy in the First Line Therapy for R/M HNSCC in China | NCT04857164 | Head and Neck S... | Pembrolizumab c... | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT05668949 | Head and Neck S... | TTI-101 Pembrolizumab | 18 Years - | M.D. Anderson Cancer Center | |
| RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma | NCT04762225 | Head and Neck S... Melanoma Cervical Cancer | RPTR-168 | 18 Years - | Repertoire Immune Medicines | |
| Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma | NCT06194656 | Head and Neck S... | HER3 Monoclonal... Cetuximab injec... Placebo | 18 Years - 75 Years | Shanghai Institute Of Biological Products | |
| Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer | NCT04110249 | Head and Neck C... Head and Neck L... Head and Neck S... Laryngeal Neopl... Radiation Thera... | Photoacoustic I... Transcutaneous ... | 18 Years - | Roswell Park Cancer Institute | |
| Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma | NCT02778191 | Head and Neck S... | cisplatin carboplatin 5-FU | 18 Years - 70 Years | University Medical Center Groningen | |
| Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC | NCT05446467 | Head and Neck S... | pembrolizumab+c... | 18 Years - 85 Years | Zhejiang Provincial People's Hospital | |
| Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | NCT04624113 | Head and Neck S... | Tazemetostat Pembrolizumab | 18 Years - | Washington University School of Medicine | |
| Specific Methylation Profiles in HNSCC | NCT04567056 | Head and Neck S... | Blood sample | 18 Years - | Aalborg University Hospital | |
| Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC | NCT02999646 | Head and Neck S... | MVX-ONCO-1 | 18 Years - | Maxivax SA | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC | NCT05047094 | Head and Neck S... Skin Cancer Metastatic Head... | Diffusing Alpha... Pembrolizumab | 18 Years - | Alpha Tau Medical LTD. | |
| Heavy Strength Training in Head and Neck Cancer Survivors | NCT06289049 | Head and Neck N... Head and Neck C... Head and Neck S... Head and Neck C... | Experimental | 18 Years - | University of Alberta | |
| Ribociclib and Spartalizumab in R/M HNSCC | NCT04213404 | Head and Neck S... | Ribociclib Spartalizumab | 20 Years - 70 Years | National Taiwan University Hospital | |
| Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | NCT03422536 | Head and Neck B... Recurrent Head ... Recurrent Oroph... Squamous Cell C... Stage IV Squamo... Stage IV Squamo... Stage IV Nasoph... Stage IV Oropha... Stage IVA Lip a... Stage IVA Nasal... Stage IVA Nasop... Stage IVA Oroph... Stage IVB Lip a... Stage IVB Nasal... Stage IVB Nasop... Stage IVB Oroph... Stage IVC Lip a... Stage IVC Nasal... Stage IVC Nasop... Stage IVC Oroph... Head and Neck C... Oropharyngeal C... HNSCC Stage IV Lip an... | Cetuximab Ficlatuzumab | 18 Years - | University of Arizona | |
| Evaluation of OE-MRI in Patients With H&N Cancer | NCT04724096 | Head and Neck S... | Oxygen Enhanced... | 18 Years - 99 Years | Nottingham University Hospitals NHS Trust | |
| HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer | NCT03578406 | Cervical Cancer Head and Neck S... | HPV E6-specific... | 18 Years - 70 Years | Xinqiao Hospital of Chongqing | |
| FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER) | NCT05432193 | Pancreatic Duct... Colorectal Canc... Esophageal Canc... Melanoma (Skin) Soft Tissue Sar... Head and Neck S... Cholangiocarcin... | [Ga-68]-PNT6555 [Lu-177]-PNT655... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma | NCT05965154 | Head and Neck S... | Carrilizumab, b... | 18 Years - 85 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab | NCT05075122 | Head and Neck S... | UV1 Sargramostim fo... Pembrolizumab i... | 18 Years - | Martin-Luther-Universität Halle-Wittenberg | |
| Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT04003025 | Head and Neck S... | 18 Years - 110 Years | Instituto do Cancer do Estado de São Paulo | ||
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | NCT05267626 | Advanced Solid ... Metastatic Canc... | AU-007 Aldesleukin | 18 Years - | Aulos Bioscience, Inc. | |
| Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck | NCT02207439 | Head and Neck S... | Nelfinavir (Vir... Chemoradiation | 18 Years - | Abramson Cancer Center at Penn Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
